 |
| Anno II | Numero 11 | Marzo 2017 |
| Comitato scientifico editoriale: Sergio Bracarda, Giacomo Cartenì, Giuseppe Procopio Editore: Intermedia – Direttore Responsabile: Mauro Boldrini |
| Notizie dalla ricerca |
| FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis |
| On November 23, 2015, the U.S. Food and Drug Administration approved nivolumab for patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. The approval was based on efficacy and safety data demonstrated in an open-label, randomized study of 821 patients with advanced RCC who progressed after at least one anti-angiogenic therapy. Patients were randomized to nivolumab or everolimus and followed for disease … |
| Continua a leggere |
| Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice |
| Nivolumab is an important new therapy option for patients with advanced renal cell carcinoma, and has a different mechanism of action compared with vascular endothelial growth factor -targeted therapies. It is a programmed death 1 immune checkpoint inhibitor antibody with response patterns, efficacy, and safety profiles that differ from those of conventional antiangiogenic or mammalian target of rapamycin inhibition therapy. This commentary discusses and evaluates the clinical … |
| Continua a leggere |
| Strategies to overcome therapeutic resistance in renal cell carcinoma |
| Renal cell cancer (RCC) is a prevalent and lethal disease. At time of diagnosis, most patients present with localized disease. For these patients, the standard of care includes nephrectomy with close monitoring thereafter. While many patients will be cured, 5-year recurrence rates range from 30% to 60%. Furthermore, nearly one-third of patients present with metastatic disease at time of diagnosis. Metastatic disease is rarely curable and typically lethal. Cytotoxic chemotherapy and radiation … |
| Continua a leggere |
| Renal cell carcinoma: molecular characterization and evolving treatment paradigms |
| The treatment landscape of advanced renal cell carcinoma (RCC) continues to shift as both new targeted therapies and immunotherapies show efficacy in treating the disease. Contemporary insights into the molecular characterization of RCC are likely to fuel the development of additional therapies. This review summarizes recent advancements in the biologic characterization of RCC and discusses newly approved therapies and ongoing studies in the treatment of advanced RCC. The Cancer … |
| Continua a leggere |
| Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents |
| From a theoretical viewpoint, combining molecularly targeted agents endowed with antiangiogenic properties with immunotherapy makes sense in treatment of metastatic renal cell carcinoma (RCC); this neoplasm is highly angiogenesis-dependent, as well as potentially immunogenic. The authors performed a literature search looking for clinical trials aimed at evaluating efficacy and tolerability of combinations (or sequences) of molecularly targeted agents and different immunotherapeutic … |
| Continua a leggere |
| Appuntamenti AIOM |
pd-L1: un Riferimento Emergente nell’Immuno-Oncologia |
| Napoli, 23 marzo 2017 Aci Castello (CT), 25 marzo 2017 Parma, 12 aprile 2017 |
| La presa in carico globale del paziente oncologico: tra appropriatezza, innovazione e sostenibilità |
| Pavia, 24 marzo 2017 Patrocinio concesso dalla Sezione Regionale AIOM Lombardia |
| Immunoterapia nei Tumori del Polmone e dell’Urotelio A che punto siamo? |
| Roma, 27 – 28 marzo 2017 |
| Young Oncologists Specialists in the Science and Art of Patient Care |
| Bologna, 29 – 30 marzo 2017 |
| La Sostenibilità Futura del Servizio Sanitario: Possibili Strategie e Sinergie |
| Firenze, 31 marzo 2017 |
| Conferenza Nazionale CIPOMO La gestione del rischio in oncologia tra sicurezza e qualità |
| Ascoli Piceno, 31 marzo – 1 aprile 2017 |
| Workshop Immuno-Oncologia |
| Padova, 7 – 8 aprile 2017 |
| DOMINO Workshop DecisiOn Making IN Oncology |
| Milano, 12 aprile 2017 Roma, 22 maggio 2017 |
| XXVII Congresso Nazionale SIUrO |
| Napoli, 20 – 22 aprile 2017 |
| Corso di immunoterapia in oncologia Prima Edizione |
| Negrar (VR), 23 – 24 maggio 2017 Iscrizioni entro il 23 aprile 2017 |
| La Real World Evidence in Italia: Stato dell’arte e prospettive Seconda Edizione |
| Roma, 27 aprile 2017 |
| AIOM: Lo stato dell’oncologia in Italia |
| Roma, 27 aprile 2017 |
| XXI Congresso Nazionale Cipomo L’Ars medica in Oncologia e i tasselli del suo mosaico |
| Palermo, 4 – 6 maggio 2017 |
| Focus On: Terapie innovative in oncologia |
| Pistoia, 12 maggio 2017 |
| L’oncologo incontra il patologo 4a Edizione |
| Arezzo, 16 – 17 maggio 2017 |
| Innovazione e nanomedicina al servizio del paziente oncologico anziano |
| Catania, 18 maggio 2017 |
| Il lato nascosto dell’evidenza Ricerca Scientifica e Decisioni Terapeutiche in Oncologia |
| Verona, 23 maggio 2017 |
| XI National Congress of the Italian Society of Immunology, Clinical Immunology and Allergology |
| Bari, 28 -31 maggio 2017 |
| Questi e altri appuntamenti si possono consultare sul sito AIOM www.aiom.it |
| Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001 Per contattare la redazione e commentare le notizie clicca qui: redazione Per consultare i numeri arretrati della newsletter clicca qui: archivio Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI |
Questo progetto è stato realizzato con il contributo incondizionato di  |